臨床検査54巻6号

2010年06月発行

今月の主題 注目されるサイトカイン 各論

造血因子と臨床応用

著者： 中畑龍俊¹

所属機関： ¹京都大学iPS細胞研究所臨床応用研究部門

ページ範囲：P.623 - P.629

　造血に関与するサイトカインのうち，造血を正に制御するものは一般的に造血因子と呼ばれ，20数種類が知られている．造血因子は造血幹細胞の分化決定には作用せず，対応する受容体を発現している細胞の増殖因子として働き，分化がもたらされると考えられる．造血因子の臨床治験が数多く行われたが，医薬品として臨床応用されるようになったものはG-CSF，エリスロポエチンなどごく一部にとどまっている．トロンボポエチン(TPO)に代わり，TPO受容体作動薬の開発が進んでいる．

参考文献

1) Ogawa M, Porter PN, Nakahata T：Renewal and commitment to differentiation of hemopoietic stem cells(an interpretive review). Blood　61：823-829, 1983

2) Tsuji K, Nakahata T：Stochastic model for multipotent hemopoietic progenitor differentiation. J Cell Physiol　139：647-653, 1989

3) Ebihara Y, Xu MJ, Manabe A, et al：Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34＋ cells. Br J Haematol　109：153-161, 2000

4) Yang FC, Watanabe S, Tsuji K, et al：Human granulocyte colony-stimulating factor(G-CSF)stimulates the in vitro and in vivo development Blood　92：4632-4640, 1998

5) Yang FC, Tsuji K, Oda A, et al：Differential effects of human granulocyte colony-stimulating factor(hG-CSF)and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice. Blood　94：950-958, 1999

6) Nishijima I, Nakahata T, Hirabayashi Y, et al：human GM-CSF receptor expressed in transgenic mice stimulates proliferation and differentiation of hemopoietic progenitors to all lineages in response to human GM-CSF. Mol Biol Cell　6：497-508, 1995

7) Nishijima I, Nakahata T, Watanabe S, et al：Hematopoietic and lymphopoietic responses in human granulocyte-macrophage colony-stimulating factor(GM-CSF)receptor transgenic mice injected with human GM-CSF. Blood　90：1031-1038, 1997

8) Kuter DJ, Begley CG. :Recombinant human thrombopoietin：basic biology and evaluation of clinical studies. Blood　100：3457-3469, 2002

9) Cwirla SE, Balasubramanian P, Duffin DJ, et al：Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science　276：1696-1699, 1997

10) Kimura T, Kaburaki H, Tsujino T, et al：A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl. FEBS Lett　428：250-254, 1998

11) de Serres M, Yeager RL, Dillberger JE, et al：Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. Stem Cells　17：316-326, 1999

12) Inagaki K, Oda T, Naka Y, et al：Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood　104：58-64, 2004

13) Wang B, Nichol JL, Sullivan JT：Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther　76：628-638, 2004

by binding to Mpl. Cytokine　25：52-60, 2004

15) Kuter DJ, Bussel JB, Lyons RM, et al：Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura：a double-blind randomised controlled trial. Lancet　371：395-403, 2008

16) Liem-Moolenaar M, Cerneus D, Molloy CJ, et al：Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans. Clin Pharmacol Ther　84：481-487, 2008

17) Bussel JB, Cheng G, Saleh MN, et al：Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med　357：2237-2247, 2007

18) McHutchison JG, Dusheiko G, Shiffman ML, et al：Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med　357：2227-2236, 2007

19) Desjardins RE, Tempel DL, Lucek R, et al：Single and multiple oral doses of AKR-501(YM477)increase the platelet count in healthy volunteers. Blood　108：477, 2006

20) Nogami W, Yoshida H, Koizumi K, et al：The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica　93：1495-1504, 2008